Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its planned Phase 3 trial for FLT201, an ...
Interested in blogging for timesofindia.com? We will be happy to have you on board as a blogger, if you have the knack for writing. Just drop in a mail at toiblogs@timesinternet.in with a brief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback